BeOne Medicines AG Announced Q1 2026 Earnings on May 6, 2026, Reporting "Product revenue reached $1.5 billion in the quarter"

BeOne Medicines AG reported first quarter 2026 product revenue of $1.5 billion. BRUKINSA global revenues totaled $1.1 billion for the quarter.

Gross margin for the first quarter improved to 89%.

The company reported first quarter GAAP net income of $227 million with GAAP diluted earnings per ADS of $1.96.

Non-GAAP net income was $375 million for the first quarter, which translates to diluted non-GAAP earnings per ADS of $3.24.

The company also generated free cash flow of $161 million in the first quarter.

Management highlighted BRUKINSA as the foundational BTK inhibitor with continued global leadership.

The company also emphasized its next-generation BCL-2 inhibitor, Sonro, which received early market reception following approval in China, and its first-in-class BTK CDAC, which shows complete BTK degradation. BeOne is advancing its solid tumor pipeline towards registration, acquiring an exclusive option to license a novel PD-1 VGF CTLA4 trispecific, BON 110.

The company highlighted that their pipeline is entering a critical phase of execution with foundational strength in hematology and a clear inflection point in solid tumors.

For full year 2026 guidance, BeOne Medicines projects revenue to be between $6.3 billion and $6.5 billion. GAAP gross margin is expected to remain in the high 80% range. GAAP operating expenses are anticipated to be between $4.7 billion and $4.9 billion. GAAP operating income estimates are updated to be between $750 million and $850 million.

The company expects a potential accelerated approval submission in the U.S. for its BTK CDAC in the second half of the year.